Overton conceded multiple times during the hearing that vaccines approved by the FDA, as well as the so-called “abortion pill ...

The National Institutes of Health's National Library of Medicine has released the pilot version of a new tool designed to ...

Eli Lilly has committed $100 million in upfront and near-term payments to InnoCare Pharma to form a five-target drug ...

Acadia Pharmaceuticals’ phase 2 Alzheimer’s disease trial has missed its primary endpoint, but the company and analysts alike ...

As two Big Pharma players in the autoimmune CAR-T space face unexpected safety setbacks, Kyverna Therapeutics is reporting long-term clinical data that showcase sustained efficacy alongside an ...

Roche has penned a backloaded $2 billion deal with hematology biotech Atavistik Bio to develop allosteric small molecules for cardiometabolic diseases. | Roche has penned a backloaded $2 billion deal ...

On Wednesday, the molecular and clinical genetics panel of the FDA’s medical devices advisory committee sat down and debated Grail’s hotly anticipated Galleri test. The tech works as a simple blood ...

Merck & Co.’s Brunello trial has hit its primary endpoint, shedding light on the effects of a trispecific diabetic macular edema (DME) drug that the Big Pharma bought in a $3 billion takeover.

Fosun Pharma subsidiary Henlius Biotech has signed a $440 million biobucks deal with California-based Amberstone Biosciences to work on T-cell engagers (TCEs).

As the U.S. government faces up to China's expanding role in the global biopharma ecosystem, one senator has been looking at the bigger picture. | Senator Todd Young (R-IN), chairman of the National ...

Immunovant has stopped development of IMVT-1402 in cutaneous lupus erythematosus after failing a midphase test, closing off ...

Boehringer Ingelheim has dived deeper into its collaboration with Variant Bio by expanding the collaboration to cover ...